| Bioactivity | Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease[1]. |
| Invitro | Semorinemab 与人 Tau 蛋白和重组食蟹猴 Tau 蛋白结合的 Kd 值分别为 3.8 和 11.2 nM[1]。Semorinemab 阻止神经元摄取低聚 Tau[1]。 |
| In Vivo | Semorinemab (3，10 和 30 mg/kg；腹腔注射，每周一次，持续 13 周) 减少 Tau 病状的转基因 (Tg) 小鼠模型中 Tau 的积累[1]。 Animal Model: |
| Name | Semorinemab |
| CAS | 2159141-27-0 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ayalon G, et al. Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease. Sci Transl Med. 2021 May 12;13(593):eabb2639. |